Phenotypes associated with this allele

• Allele Symbol: Tg(Col1a1-cre/Esr1*)1Mis
• Allele Name: transgene insertion 1, Yuji Mishina
• Allele ID: MGI:3829219
• Summary: 2 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Bmpr1a^tm2.1Bhr/Bmpr1a^tm2.1Bhr Tg(Col1a1-cre/Esr1*)1Mis/0	involves: 129S7/SvEvBrd	MGI:3829249
cn2	Tg(CAG-lacZ,-BMPR1A*,-EGFP)1Mis/0 Tg(Col1a1-cre/Esr1*)1Mis/0	Not Specified	MGI:3829250

Genotype
MGI:3829249

cn1

• Allelic Composition: Bmpr1a^tm2.1Bhr/Bmpr1a^tm2.1Bhr; Tg(Col1a1-cre/Esr1*)1Mis/0
• Genetic Background: involves: 129S7/SvEvBrd

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

skeleton

abnormal skeleton morphology ( J:143588 )

enlarged parietal bone ( J:143588 )

• at E18.5, the parietal bone of tamoxifen-treated mice is thicker than in wild-type mice

abnormal bone structure ( J:143588 )

• bony areas of tamoxifen-treated mice are loose, discontinuous and disorganized compared to in wild-type mice

abnormal osteoclast differentiation ( J:143588 )

• as determined by marker expression, tamoxifen-treated mice exhibit reduced osteoclastogenesis compared to wild-type mice

decreased osteoclast cell number ( J:143588 )

• in tamoxifen-treated mice

increased bone mass ( J:143588 )

• at E18.5, tamoxifen-treated mice exhibit a 30% increase in bone volume to total tissue volume in the calvariae and femora compared to wild-type mice

• tamoxifen-treated mice exhibit increased bone mass in femora and calvariae compared to in wild-type mice

abnormal skeleton physiology ( J:143588 )

abnormal osteoclast physiology ( J:143588 )

• tamoxifen-treated mice exhibit reduced osteoclast activity compared to in wild-type mice

increased bone mineralization ( J:143588 )

• bone mineralization of calvariae from mice treated with tamoxifen is increased and bone continuity is disrupted compared to in wild-type mice

decreased bone ossification ( J:143588 )

• as determined by expression of markers, tamoxifen-treated mice exhibit a modest reduction in E16.5 bone formation compared to in wild-type mice

immune system

abnormal osteoclast differentiation ( J:143588 )

• as determined by marker expression, tamoxifen-treated mice exhibit reduced osteoclastogenesis compared to wild-type mice

decreased osteoclast cell number ( J:143588 )

• in tamoxifen-treated mice

abnormal osteoclast physiology ( J:143588 )

• tamoxifen-treated mice exhibit reduced osteoclast activity compared to in wild-type mice

hematopoietic system

abnormal osteoclast differentiation ( J:143588 )

• as determined by marker expression, tamoxifen-treated mice exhibit reduced osteoclastogenesis compared to wild-type mice

decreased osteoclast cell number ( J:143588 )

• in tamoxifen-treated mice

abnormal osteoclast physiology ( J:143588 )

• tamoxifen-treated mice exhibit reduced osteoclast activity compared to in wild-type mice

craniofacial

enlarged parietal bone ( J:143588 )

• at E18.5, the parietal bone of tamoxifen-treated mice is thicker than in wild-type mice

cellular

abnormal osteoclast differentiation ( J:143588 )

• as determined by marker expression, tamoxifen-treated mice exhibit reduced osteoclastogenesis compared to wild-type mice

Genotype
MGI:3829250

cn2

• Allelic Composition: Tg(CAG-lacZ,-BMPR1A*,-EGFP)1Mis/0; Tg(Col1a1-cre/Esr1*)1Mis/0
• Genetic Background: Not Specified

skeleton

thin neurocranium ( J:143588 )

• at E18.5, tamoxifen-treated mice exhibit moderately thinner calvariae than wild-type mice

decreased bone mass ( J:143588 )

• at E18.5, tamoxifen-treated mice exhibit a moderately thinner calvariae than in wild-type mice

craniofacial

thin neurocranium ( J:143588 )

• at E18.5, tamoxifen-treated mice exhibit moderately thinner calvariae than wild-type mice